

Getting started with Cortellis Competitive Intelligence


What is Cortellis Competitive Intelligence?

Cortellis Competitive Intelligence gives you accurate up-to-date information on global drug pipelines, companies, deals and patents, plus breaking industry news, clinical trials and conferences. *Cortellis* allows you to keep a constant watch on competitors, summarize and prioritize the product pipelines in your area of research, monitor new patent filings, and assess the attractiveness of the companies you are interested in.

Quick search

To start searching use the **Quick Search** box located at the top of the page. Quick Search enables you to search for single or multiple terms, in any combination. Boolean operators AND, OR, and NOT can be used if needed, as well as an asterisk as a truncation indicator.

Start typing in the search box and select the term(s) suggested by the autocomplete feature, if relevant, and then click the **Search** button.



Results page

The results are displayed in a table format ranked by relevance. The **relevancy** is determined according to where in the record the searched terms are found and how often they occur in the report.

On the left hand side of the page, under **Report Type**, you will find the number of reports that contain the searched term(s), broken down by report types. By default, the drug reports are displayed. If you want to view other types of reports, simply click on the report type of interest.

2652 results found for "multiple sclerosis"

Report Type	Results	Per page: 100	Sort by: Relevance	Descending	Order Columns	View																								
<ul style="list-style-type: none"> Broker Research (65995) Clinical Trials (5299) Companies (1872) Conferences (2543) Deals (1478) Disease Briefings (26) Drugs (2652) Event Transcripts (2291) Literature (5999) Patents (19270) Press Releases (13247) Regulatory (3924) Venture Funding (0) 	<table border="1"> <thead> <tr> <th>Drug Name</th> <th>Other Drug Names</th> <th>Active Companies</th> <th>Active Indications</th> <th>Highest Status</th> <th>Target-based Actions</th> </tr> </thead> <tbody> <tr> <td>fampridine (oral, sustained release, multiple sclerosis/spinal cord injury), Acorda/Biogen</td> <td>4-AP; 4-Aminopyridine; Amaya; Ampyra; BIB-041; EL-970; Fampridine SR; Fampyra; IPDAS (fampridine); Neurelan; dalfampridine; dalfampridine ER; fampridine; fampridine (oral, sustained release, multiple sclerosis/spinal cord injury)</td> <td>Acorda Therapeutics Inc; Biogen Inc; Stenchal International; UCB SA</td> <td>Multiple sclerosis</td> <td>Launched (Multiple sclerosis - Puerto Rico - Mar-2010; Multiple sclerosis - US - Mar-2010)</td> <td>Potassium channel inhibitor</td> </tr> <tr> <td>dirucotide (iv, multiple sclerosis), BioMS Medical/Eli Lilly</td> <td>MBP-8208; MBP-8298; SF-328; dirucotide; dirucotide (iv, multiple sclerosis), BioMS Medical/Eli Lilly; dirucotide acetate; multiple sclerosis therapy, BioMS; multiple sclerosis therapy, Briana; multiple sclerosis therapy, <i>Hydroxy of thea...</i></td> <td></td> <td></td> <td>Discontinued</td> <td>Myelin basic protein modulator</td> </tr> <tr> <td>peginterferon beta-1a (multiple sclerosis), Biogen</td> <td>BIB-017; PEG-Avonex; PEGylated IFN beta 1-a (multiple sclerosis), Biogen; PEGylated IFN beta 1-a (multiple sclerosis), Biogen Idex; PEGylated interferon beta 1-a (multiple sclerosis), Biogen; PEGylated interferon</td> <td>Biogen Inc; Eisai Co Ltd; UCB SA</td> <td>Multiple sclerosis</td> <td>Launched (Multiple sclerosis - Denmark - Sep-2014; Multiple sclerosis - EU - Sep-2014; Multiple sclerosis - Germany Sep-2014)</td> <td>Interferon beta ligand</td> </tr> </tbody> </table>	Drug Name	Other Drug Names	Active Companies	Active Indications	Highest Status	Target-based Actions	fampridine (oral, sustained release, multiple sclerosis/spinal cord injury), Acorda/Biogen	4-AP; 4-Aminopyridine; Amaya; Ampyra; BIB-041; EL-970; Fampridine SR; Fampyra; IPDAS (fampridine); Neurelan; dalfampridine; dalfampridine ER; fampridine; fampridine (oral, sustained release, multiple sclerosis/spinal cord injury)	Acorda Therapeutics Inc; Biogen Inc; Stenchal International; UCB SA	Multiple sclerosis	Launched (Multiple sclerosis - Puerto Rico - Mar-2010; Multiple sclerosis - US - Mar-2010)	Potassium channel inhibitor	dirucotide (iv, multiple sclerosis), BioMS Medical/Eli Lilly	MBP-8208; MBP-8298; SF-328; dirucotide; dirucotide (iv, multiple sclerosis), BioMS Medical/Eli Lilly; dirucotide acetate; multiple sclerosis therapy, BioMS; multiple sclerosis therapy, Briana; multiple sclerosis therapy, <i>Hydroxy of thea...</i>			Discontinued	Myelin basic protein modulator	peginterferon beta-1a (multiple sclerosis), Biogen	BIB-017; PEG-Avonex; PEGylated IFN beta 1-a (multiple sclerosis), Biogen; PEGylated IFN beta 1-a (multiple sclerosis), Biogen Idex; PEGylated interferon beta 1-a (multiple sclerosis), Biogen; PEGylated interferon	Biogen Inc; Eisai Co Ltd; UCB SA	Multiple sclerosis	Launched (Multiple sclerosis - Denmark - Sep-2014; Multiple sclerosis - EU - Sep-2014; Multiple sclerosis - Germany Sep-2014)	Interferon beta ligand	100	Relevance	Descending		1 2 3 4 5 6 7 8 9 Next Last
Drug Name	Other Drug Names	Active Companies	Active Indications	Highest Status	Target-based Actions																									
fampridine (oral, sustained release, multiple sclerosis/spinal cord injury), Acorda/Biogen	4-AP; 4-Aminopyridine; Amaya; Ampyra; BIB-041; EL-970; Fampridine SR; Fampyra; IPDAS (fampridine); Neurelan; dalfampridine; dalfampridine ER; fampridine; fampridine (oral, sustained release, multiple sclerosis/spinal cord injury)	Acorda Therapeutics Inc; Biogen Inc; Stenchal International; UCB SA	Multiple sclerosis	Launched (Multiple sclerosis - Puerto Rico - Mar-2010; Multiple sclerosis - US - Mar-2010)	Potassium channel inhibitor																									
dirucotide (iv, multiple sclerosis), BioMS Medical/Eli Lilly	MBP-8208; MBP-8298; SF-328; dirucotide; dirucotide (iv, multiple sclerosis), BioMS Medical/Eli Lilly; dirucotide acetate; multiple sclerosis therapy, BioMS; multiple sclerosis therapy, Briana; multiple sclerosis therapy, <i>Hydroxy of thea...</i>			Discontinued	Myelin basic protein modulator																									
peginterferon beta-1a (multiple sclerosis), Biogen	BIB-017; PEG-Avonex; PEGylated IFN beta 1-a (multiple sclerosis), Biogen; PEGylated IFN beta 1-a (multiple sclerosis), Biogen Idex; PEGylated interferon beta 1-a (multiple sclerosis), Biogen; PEGylated interferon	Biogen Inc; Eisai Co Ltd; UCB SA	Multiple sclerosis	Launched (Multiple sclerosis - Denmark - Sep-2014; Multiple sclerosis - EU - Sep-2014; Multiple sclerosis - Germany Sep-2014)	Interferon beta ligand																									

Filters

If you wish to refine your results, you can apply **Filters** found on the left hand side of the page. The filters available will vary according to the report type displayed. Drugs can be filtered by indications, companies, development status or total forecast sales, among others.

For example, to narrow down to drugs in clinical phases for your indication, click on **Show all filters**. Select the indication(s) of interest (**Hierarchical List** is recommended in order to include sub-terms) and then click on **Status** to select the relevant phase(s).

Refine Search

Search within Results

Search

▼ Indication

- Multiple sclerosis (742)
- Rheumatoid arthritis (260)
- Cancer (246)
- Show all filters**

► Company

► Status

SHOW ALL FILTERS

Search Indication **Look up**

Non-Hierarchical List

Hierarchical List


- Indication **1**
- Company
- Status **2**
- Country
- Target-based Actions
- Other Actions
- Technologies
- Added Date
- Last Change Date
- Highest Status
- Highest Status at Termination
- Regulatory Designations
- Total Reported Sales 2016 (USD M)
- Total Forecast Sales 2022 (USD M)
- Sales and Forecast Data
- Number of Active Deals

- Gynecology and obstetrics (190)
- Hematological disease (364)
- Immune disorder (1318)
 - Allergy (155)
 - Autoimmune disease (1103)
 - Antiphospholipid syndrome (1)
 - Autoimmune hemolytic anemia (3)
 - Autoimmune hepatitis (2)
 - Autoimmune nervous system disease (2)
 - Behcets disease (11)
 - Crohns disease (70)
 - Cutaneous lupus erythematosus (3)
 - Graves disease (1)
 - Guillain Barre syndrome (4)
 - Lupus nephritis (17)
 - Multiple sclerosis (731)
 - Myasthenia gravis (24)
 - Paroxysmal nocturnal hemoglobinuria (2)
 - Primary biliary cirrhosis (4)
 - Psoriasis (132)
 - Psoriatic arthritis (32)


Cancel **Apply**

Other options


You can change the display of your results by selecting one of the available **View** options, located above the results on the right. For example, see **Rank by View** of top 10 companies in the screenshot below



You can **Save** your queries and create email **Alerts** to automatically receive new and/or updated information, as well as **Download** your results into a variety of formats.



You can also use the Analyze feature to create interactive visualizations of your competitive landscape. For example, see Funnel analysis in the screenshot below:



For more information contact Customer Service at [LS Product Support](#)